Abstract
Breast cancer is a multifactorial heterogeneous disease, reflected in a wide range of phenotypic subsets of tumors with varied degrees of aggressiveness and a significant global impact on women’s health. In addition to defining the profiles of breast tumors, it is necessary to identify the individual gene and protein expression aberrations and their impact on the biology of the tumor. Molecular pathology changed the way we think about the classification of breast cancer, by no longer relying on just the histological alterations, but also on their biologic pathways. However, it should be noted that although the identification of breast cancer genes contributes to the detection of precursor lesions and prevention of invasive disease, a correlation between phenotype and genotype is necessary, as the sole assessment of gene alterations is insufficient for the identification of predictive and prognostic factors allowing the application of new and individualized cancer therapies. In conclusion, this chapter focuses on the basic molecular pathology knowledge needed in everyday routine practice.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
Russo J, Yun-Fu H, Xiaoqi Y, Russo IH. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr. 2000;27:17–37.
Bannasch P. Cancer diagnosis: early detection. New York, NY: Springer; 1992. p. 170.
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533–46.
Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378:1812–23.
Gomez-Wolff R, Garcia H, Ossa C. Impact of “immunohistochemistry-based molecular subtype” on chemo-sensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy (NAC) [abstract]. In: Proceedings of the 2016 San Antonio breast cancer symposium; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res. 2017;77(4 Suppl):Abstract no. P5-16-20.
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.
Kimberly H, Allison MD. Molecular pathology of breast cancer: what a pathologist needs to know. Am J Clin Pathol. 2012;138(6):770–80.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes—dealing with the diversity of breast cancer–highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47.
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206–23.
Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012;14:R129.
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–74.
Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175–80.
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98.
Tian S, Roepman P, Van’t Veer LJ, Bernards R, de Snoo F, Glas AM. Biological functions of the genes in the MammaPrint breast cancer profile reflect the hallmarks of cancer. Biomark Insights. 2010;5:129–38.
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1–2):4–13.
Halilovic A, Bulte J, Jacobs Y, Braam H, van Cleef P, Schlooz-Vries M, et al. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu. J Clin Pathol. 2017;70(9):781–6.
Lee EYHP, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010;2(10):a003236.
Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: Implications for human breast cancer. Oncogene. 2007b;26:1338–45.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.
Van de Vijver MJ. Molecular genetic changes in breast cancer. In: Weinberg RA, editor. Oncogenes and the molecular origins of cancer. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989. p. 25–60.
Chial H. Tumor suppressor (TS) genes and the two-hit hypothesis. Nat Educ. 2008;1(1):177.
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–33.
Krawczyk N, Hartkopf A, Banys M, Meier-Stiegen F, Staebler A, Wallwiener M, et al. Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients. BMC Cancer. 2014;14:394.
Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, et al. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer. 2016;16:522.
Wu CY, Du SL, Zhang J, Liang AL, Liu YJ. Exosomes and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment. Cancer Gene Ther. 2017;24:6–12.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Comanescu, M. (2018). Basic Molecular Pathology in Breast Carcinoma. In: Stolnicu, S., Alvarado-Cabrero, I. (eds) Practical Atlas of Breast Pathology . Springer, Cham. https://doi.org/10.1007/978-3-319-93257-6_19
Download citation
DOI: https://doi.org/10.1007/978-3-319-93257-6_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-93256-9
Online ISBN: 978-3-319-93257-6
eBook Packages: MedicineMedicine (R0)